10

Sinopharm

- HK:1099
Last Updated 2024-04-16

LinkedIn Profile

Access Sinopharm historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
hk:1099 1971997 Apr 14th, 2024 12:00AM Sinopharm 7.6K 454.00 Open Apr 14th, 2024 02:01AM Apr 14th, 2024 02:01AM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 13th, 2024 12:00AM Sinopharm 7.6K 454.00 Open Apr 13th, 2024 01:22AM Apr 13th, 2024 01:42PM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 12th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 12th, 2024 01:34AM Apr 12th, 2024 10:43AM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 11th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 11th, 2024 03:44AM Apr 11th, 2024 01:25PM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 10th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 10th, 2024 01:30AM Apr 10th, 2024 07:30PM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 9th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 9th, 2024 01:57AM Apr 9th, 2024 12:12PM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 8th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 8th, 2024 02:34AM Apr 8th, 2024 09:08PM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 7th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 7th, 2024 02:11AM Apr 7th, 2024 02:11AM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 6th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 6th, 2024 01:49AM Apr 6th, 2024 01:49AM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm
hk:1099 1971997 Apr 5th, 2024 12:00AM Sinopharm 7.6K 453.00 Open Apr 5th, 2024 04:31AM Apr 5th, 2024 04:31AM China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA. Open medical distribution & logistics, medicinal retail, bio-pharm, pharmaceutical production, traditional & herbal medicine, medical devices production & sale, import & export, R & D & production of chemical & diagnosis reagent, pharmaceutical R&D & design, and exhibit Open Sinopharm

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.